Drug Trial Radar · NCT05620823
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
608
Actual
Start
Dec 19, 2022
Primary completion
Feb 3, 2025
Study completion Dec 23, 2025
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Nov 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo controlled period, followed by a 42-week extension period.
Conditions
- Hidradenitis Suppurativa (HS)
Interventions
PovorcitinibDrug
Oral; Tablet
PlaceboDrug
Oral; Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response (HiSCR)Time frame: Week 12
Locations
104 sites in 12 countries. Site status is shown where the registry gives one.
Investigative Site US303
Phoenix, Arizona
Investigative Site US335
Arkansas City, Arkansas
Investigative Site US307
Fort Smith, Arkansas
Investigative Site US315
Laguna Niguel, California
Investigative Site US326
Los Angeles, California
Investigative Site US323
San Francisco, California
Investigative Site US306
Boca Raton, Florida
Investigative Site US320
Boca Raton, Florida
Investigative Site US317
Hialeah, Florida
Investigative Site US338
Margate, Florida
Investigative Site US321
North Miami Beach, Florida
Investigative Site US316
Orlando, Florida
Investigative Site US328
Tampa, Florida
Investigative Site US336
Tampa, Florida
Investigative Site US311
Marietta, Georgia
Investigative Site US327
Chicago, Illinois
Investigative Site US319
Skokie, Illinois
Investigative Site US337
Indianapolis, Indiana
Investigative Site US341
Bowling Green, Kentucky
Investigative Site US334
Metairie, Louisiana
Investigative Site US333
Baltimore, Maryland
Investigative Site US325
Columbia, Maryland
Investigative Site US318
Beverly, Massachusetts
Investigative Site US304
Boston, Massachusetts
Investigative Site US310
Brighton, Massachusetts
Investigative Site US302
St Louis, Missouri
Investigative Site US331
Albuquerque, New Mexico
Investigative Site US324
Kew Gardens, New York
Investigative Site US339
Bexley, Ohio
Investigative Site US330
Boardman, Ohio
Investigative Site US314
Cincinnati, Ohio
Investigative Site US312
Cleveland, Ohio
Investigative Site US301
Portland, Oregon
Investigative Site US340
Bellaire, Texas
Investigative Site US300
Plano, Texas
Investigative Site US313
Norfolk, Virginia
Investigative Site US308
Spokane, Washington
Investigative Site AT304
Graz, Austria
Investigative Site 00A
Innsbruck, Austria
Investigative Site AT306
Innsbruck, Austria
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.